Abstract
The promise of pharmacogenomics lies in the potential to establish a personalized drug therapy with the intent of maximizing effectiveness and minimizing risk, through development of pharmacogenomics biomarkers. However, currently, most pharmacogenomic measurements are not considered valid biomarkers with clear clinical significance, thus this field is in early developmental stages. Recently, the development of comprehensive, high-throughput technologies such as gene expression microarrays has provided powerful new tools for these stages. This technological transformation is, at the same time, generating an increasing demand for statistical analysis of large and complex multivariate datasets from high-throughput assays. This article provides a review of the key features to be observed in statistical analyses of large amounts of data from pharmacogenomic biomarker studies with high-throughput assays. The problem of false positive can be very serious in such studies. The evaluation of stability and reproducibility of the results of statistical analysis are claimed to reduce chance that false positive findings are subject to further investigation in subsequent studies.
Keywords: Pharmacogenomics, biomarkers, high-throughput technology, statistical analysis, false positives
Current Drug Safety
Title: Reducing False Positive Findings in Statistical Analysis of Pharmacogenomic Biomarker Studies Using High-Throughput Technologies
Volume: 1 Issue: 2
Author(s): Shigeyuki Matsui
Affiliation:
Keywords: Pharmacogenomics, biomarkers, high-throughput technology, statistical analysis, false positives
Abstract: The promise of pharmacogenomics lies in the potential to establish a personalized drug therapy with the intent of maximizing effectiveness and minimizing risk, through development of pharmacogenomics biomarkers. However, currently, most pharmacogenomic measurements are not considered valid biomarkers with clear clinical significance, thus this field is in early developmental stages. Recently, the development of comprehensive, high-throughput technologies such as gene expression microarrays has provided powerful new tools for these stages. This technological transformation is, at the same time, generating an increasing demand for statistical analysis of large and complex multivariate datasets from high-throughput assays. This article provides a review of the key features to be observed in statistical analyses of large amounts of data from pharmacogenomic biomarker studies with high-throughput assays. The problem of false positive can be very serious in such studies. The evaluation of stability and reproducibility of the results of statistical analysis are claimed to reduce chance that false positive findings are subject to further investigation in subsequent studies.
Export Options
About this article
Cite this article as:
Matsui Shigeyuki, Reducing False Positive Findings in Statistical Analysis of Pharmacogenomic Biomarker Studies Using High-Throughput Technologies, Current Drug Safety 2006; 1 (2) . https://dx.doi.org/10.2174/157488606776930517
DOI https://dx.doi.org/10.2174/157488606776930517 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Short-Term Intra-Nasal Erythropoietin Administration with Low Sialic Acid Content is without Toxicity or Erythropoietic Effects
Current Neurovascular Research Irradiation Toxicity and Inflammatory Bowel Diseases (IBD): Review
Reviews on Recent Clinical Trials Ascorbic Acid in Cancer Chemoprevention: Translational Perspectives and Efficacy
Current Drug Targets Secreted Heat Shock Protein-90α: A More Effective and Safer Target for Anti-Cancer Drugs?
Current Signal Transduction Therapy Role of Unani Medicines in Cancer Control and Management
Current Drug Therapy Noble metal-dithiocarbamates precious allies in the fight against cancer
Mini-Reviews in Medicinal Chemistry Recent Advances in the Synthesis and Applications of Multimodal Gold-Iron Nanoparticles
Current Medicinal Chemistry Current Clinical Applications of Botulinum Toxin
Current Pharmaceutical Design The Role of the Transcription Factor E2F1 in Hepatocellular Carcinoma
Current Drug Delivery Selenium and Selenoproteins: An Overview on Different Biological Systems
Current Protein & Peptide Science A Search for Inhibitors of S100B, a Member of the S100 Family of Calcium-Binding Proteins
Mini-Reviews in Medicinal Chemistry Approaching Neurological Diseases to Reduce Mobility Limitations in Older Persons
Current Pharmaceutical Design Anticancer Properties of Amino Acid and Peptide Derivatives of Mycophenolic Acid
Anti-Cancer Agents in Medicinal Chemistry Meet the Editorial Board Member
Recent Advances in Drug Delivery and Formulation Exploring the Mitochondrial Apoptotic Cell Death Landscape and Associated Components Serving as Molecular Targets, Primarily for Synthetic and Natural Drugs Targeting Oncology Therapeutics
Current Molecular Pharmacology Ellagic Acid Enhances the Efficacy of PI3K Inhibitor GDC-0941 in Breast Cancer Cells
Current Molecular Medicine Discussion on the Structural Modification and Anti-tumor Activity of Flavonoids
Current Topics in Medicinal Chemistry The Involvement of ERCC2/XPD and ERCC6/CSB Wild Type Alleles in Protection Against Aging and Cancer
Current Aging Science Cisplatin Properties in a Nanobiotechnological Approach to Cancer: A Mini-Review
Current Cancer Drug Targets Preface: [Hot topic: Metal Compounds in Medicinal Chemistry (Executive Editor: Dinorah Gambino)]
Mini-Reviews in Medicinal Chemistry